vs

Side-by-side financial comparison of ARTIVION, INC. (AORT) and Emerald Holding, Inc. (EEX). Click either name above to swap in a different company.

Emerald Holding, Inc. is the larger business by last-quarter revenue ($132.7M vs $116.0M, roughly 1.1× ARTIVION, INC.). ARTIVION, INC. runs the higher net margin — 2.1% vs -22.8%, a 24.8% gap on every dollar of revenue. On growth, Emerald Holding, Inc. posted the faster year-over-year revenue change (24.3% vs 19.2%). Emerald Holding, Inc. produced more free cash flow last quarter ($11.7M vs $-7.9M). Over the past eight quarters, ARTIVION, INC.'s revenue compounded faster (9.1% CAGR vs -0.3%).

Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.

TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.

AORT vs EEX — Head-to-Head

Bigger by revenue
EEX
EEX
1.1× larger
EEX
$132.7M
$116.0M
AORT
Growing faster (revenue YoY)
EEX
EEX
+5.1% gap
EEX
24.3%
19.2%
AORT
Higher net margin
AORT
AORT
24.8% more per $
AORT
2.1%
-22.8%
EEX
More free cash flow
EEX
EEX
$19.6M more FCF
EEX
$11.7M
$-7.9M
AORT
Faster 2-yr revenue CAGR
AORT
AORT
Annualised
AORT
9.1%
-0.3%
EEX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AORT
AORT
EEX
EEX
Revenue
$116.0M
$132.7M
Net Profit
$2.4M
$-30.2M
Gross Margin
63.1%
Operating Margin
9.2%
-11.8%
Net Margin
2.1%
-22.8%
Revenue YoY
19.2%
24.3%
Net Profit YoY
114.7%
-692.2%
EPS (diluted)
$0.06
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AORT
AORT
EEX
EEX
Q4 25
$116.0M
$132.7M
Q3 25
$113.4M
$77.5M
Q2 25
$113.0M
$105.5M
Q1 25
$99.0M
$147.7M
Q4 24
$97.3M
$106.8M
Q3 24
$95.8M
$72.6M
Q2 24
$98.0M
$86.0M
Q1 24
$97.4M
$133.4M
Net Profit
AORT
AORT
EEX
EEX
Q4 25
$2.4M
$-30.2M
Q3 25
$6.5M
$-14.4M
Q2 25
$1.3M
$-1.4M
Q1 25
$-505.0K
$15.3M
Q4 24
$-16.5M
$5.1M
Q3 24
$-2.3M
$-11.1M
Q2 24
$-2.1M
$-2.8M
Q1 24
$7.5M
$11.0M
Gross Margin
AORT
AORT
EEX
EEX
Q4 25
63.1%
Q3 25
65.6%
Q2 25
64.7%
Q1 25
64.2%
Q4 24
63.2%
Q3 24
63.7%
Q2 24
64.6%
Q1 24
64.6%
Operating Margin
AORT
AORT
EEX
EEX
Q4 25
9.2%
-11.8%
Q3 25
11.1%
-10.1%
Q2 25
7.4%
9.7%
Q1 25
2.2%
24.2%
Q4 24
2.7%
19.5%
Q3 24
4.6%
-6.5%
Q2 24
6.6%
7.4%
Q1 24
26.0%
18.2%
Net Margin
AORT
AORT
EEX
EEX
Q4 25
2.1%
-22.8%
Q3 25
5.7%
-18.6%
Q2 25
1.2%
-1.3%
Q1 25
-0.5%
10.4%
Q4 24
-16.9%
4.8%
Q3 24
-2.4%
-15.3%
Q2 24
-2.2%
-3.3%
Q1 24
7.7%
8.2%
EPS (diluted)
AORT
AORT
EEX
EEX
Q4 25
$0.06
$-0.15
Q3 25
$0.13
$-0.07
Q2 25
$0.03
$-0.01
Q1 25
$-0.01
$0.08
Q4 24
$-0.40
$0.01
Q3 24
$-0.05
$-0.05
Q2 24
$-0.05
$-0.03
Q1 24
$0.18
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AORT
AORT
EEX
EEX
Cash + ST InvestmentsLiquidity on hand
$64.9M
$100.9M
Total DebtLower is stronger
$215.1M
Stockholders' EquityBook value
$448.2M
$338.8M
Total Assets
$884.8M
$1.2B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AORT
AORT
EEX
EEX
Q4 25
$64.9M
$100.9M
Q3 25
$73.4M
$95.4M
Q2 25
$53.5M
$156.4M
Q1 25
$37.7M
$276.8M
Q4 24
$53.5M
$194.8M
Q3 24
$56.2M
$188.9M
Q2 24
$55.0M
$193.2M
Q1 24
$51.1M
$186.8M
Total Debt
AORT
AORT
EEX
EEX
Q4 25
$215.1M
Q3 25
$214.9M
Q2 25
$215.6M
Q1 25
$314.7M
Q4 24
$314.3M
Q3 24
$314.0M
Q2 24
$313.6M
Q1 24
$313.3M
Stockholders' Equity
AORT
AORT
EEX
EEX
Q4 25
$448.2M
$338.8M
Q3 25
$438.7M
$369.5M
Q2 25
$419.9M
$389.4M
Q1 25
$294.3M
$392.1M
Q4 24
$276.2M
$385.9M
Q3 24
$304.7M
$391.1M
Q2 24
$295.1M
$407.6M
Q1 24
$295.0M
$-90.7M
Total Assets
AORT
AORT
EEX
EEX
Q4 25
$884.8M
$1.2B
Q3 25
$857.7M
$1.2B
Q2 25
$838.4M
$1.2B
Q1 25
$791.2M
$1.2B
Q4 24
$789.1M
$1.0B
Q3 24
$803.1M
$1.1B
Q2 24
$789.5M
$1.1B
Q1 24
$784.0M
$1.1B
Debt / Equity
AORT
AORT
EEX
EEX
Q4 25
0.48×
Q3 25
0.49×
Q2 25
0.51×
Q1 25
1.07×
Q4 24
1.14×
Q3 24
1.03×
Q2 24
1.06×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AORT
AORT
EEX
EEX
Operating Cash FlowLast quarter
$19.6M
$12.3M
Free Cash FlowOCF − Capex
$-7.9M
$11.7M
FCF MarginFCF / Revenue
-6.9%
8.8%
Capex IntensityCapex / Revenue
23.7%
0.5%
Cash ConversionOCF / Net Profit
8.06×
TTM Free Cash FlowTrailing 4 quarters
$839.0K
$41.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AORT
AORT
EEX
EEX
Q4 25
$19.6M
$12.3M
Q3 25
$22.3M
$1.8M
Q2 25
$15.0M
$15.9M
Q1 25
$-17.0M
$12.6M
Q4 24
$10.1M
$20.6M
Q3 24
$11.5M
$9.1M
Q2 24
$6.1M
$9.8M
Q1 24
$-5.5M
$7.3M
Free Cash Flow
AORT
AORT
EEX
EEX
Q4 25
$-7.9M
$11.7M
Q3 25
$17.7M
$1.5M
Q2 25
$11.7M
$15.8M
Q1 25
$-20.6M
$12.4M
Q4 24
$8.7M
$19.9M
Q3 24
$7.8M
$9.0M
Q2 24
$3.6M
$9.6M
Q1 24
$-9.1M
$7.0M
FCF Margin
AORT
AORT
EEX
EEX
Q4 25
-6.9%
8.8%
Q3 25
15.6%
1.9%
Q2 25
10.4%
15.0%
Q1 25
-20.8%
8.4%
Q4 24
9.0%
18.6%
Q3 24
8.2%
12.4%
Q2 24
3.7%
11.2%
Q1 24
-9.3%
5.2%
Capex Intensity
AORT
AORT
EEX
EEX
Q4 25
23.7%
0.5%
Q3 25
4.1%
0.4%
Q2 25
2.9%
0.1%
Q1 25
3.7%
0.1%
Q4 24
1.5%
0.7%
Q3 24
3.8%
0.1%
Q2 24
2.6%
0.2%
Q1 24
3.7%
0.2%
Cash Conversion
AORT
AORT
EEX
EEX
Q4 25
8.06×
Q3 25
3.42×
Q2 25
11.16×
Q1 25
0.82×
Q4 24
4.04×
Q3 24
Q2 24
Q1 24
-0.73×
0.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AORT
AORT

Aortic Stent Grafts$43.3M37%
On X$27.8M24%
Preservation Services$24.1M21%
Surgical Sealants$20.3M18%
Other Products$463.0K0%

EEX
EEX

Connections Segment$121.9M92%
Commerce Segment$5.5M4%
Content$5.3M4%

Related Comparisons